EGFR and non-small cell lung carcinoma: In 2010, a clinical trial comparing gefitinib and chemotherapy showed superiority of the targeted treatment, with PFS of 9.2 months on gefitinib compared to 6.3 months on cisplatin and docetaxel, establishing EGFR-TKIs as first-line treatment in EGFR-mutant NSCLC.56